Form 8-K - Current report:
SEC Accession No. 0001104659-25-044126
Filing Date
2025-05-02
Accepted
2025-05-02 16:20:28
Documents
14
Period of Report
2025-05-02
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2513881d1_8k.htm   iXBRL 8-K 29594
2 EXHIBIT 99.1 tm2513881d1_ex99-1.htm EX-99.1 8644
  Complete submission text file 0001104659-25-044126.txt   218664

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rnaz-20250502.xsd EX-101.SCH 3053
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rnaz-20250502_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rnaz-20250502_pre.xml EX-101.PRE 22384
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2513881d1_8k_htm.xml XML 3799
Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Filer) CIK: 0001829635 (see all company filings)

EIN.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40363 | Film No.: 25908872
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)